SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Sjöstedt J.)
 

Search: WFRF:(Sjöstedt J.) > Modern Development ...

  • Conlan, J. Wayne (author)

Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 Delta clpB, to Prevent Tularemia

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-06-23
  • MDPI,2021
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-187297
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-187297URI
  • https://doi.org/10.3390/pathogens10070795DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Inhalation of small numbers of Francisella tularensis subspecies tularensis (Ftt) in the form of small particle aerosols causes severe morbidity and mortality in people and many animal species. For this reason, Ftt was developed into a bona fide biological weapon by the USA, by the former USSR, and their respective allies during the previous century. Although such weapons were never deployed, the 9/11 attack quickly followed by the Amerithrax attack led the U.S. government to seek novel countermeasures against a select group of pathogens, including Ftt. Between 2005-2009, we pursued a novel live vaccine against Ftt by deleting putative virulence genes from a fully virulent strain of the pathogen, SCHU S4. These mutants were screened in a mouse model, in which the vaccine candidates were first administered intradermally (ID) to determine their degree of attenuation. Subsequently, mice that survived a high dose ID inoculation were challenged by aerosol or intranasally (IN) with virulent strains of Ftt. We used the current unlicensed live vaccine strain (LVS), first discovered over 70 years ago, as a comparator in the same model. After screening 60 mutants, we found only one, SCHU S4 Delta clpB, that outperformed LVS in the mouse ID vaccination-respiratory-challenge model. Currently, SCHU S4 Delta clpB has been manufactured under current good manufacturing practice conditions, and tested for safety and efficacy in mice, rats, and macaques. The steps necessary for advancing SCHU S4 Delta clpB to this late stage of development are detailed herein. These include developing a body of data supporting the attenuation of SCHU S4 Delta clpB to a degree sufficient for removal from the U.S. Select Agent list and for human use; optimizing SCHU S4 Delta clpB vaccine production, scale up, and long-term storage; and developing appropriate quality control testing approaches.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sjöstedt, AndersUmeå universitet,Molekylär Infektionsmedicin, Sverige (MIMS),Institutionen för klinisk mikrobiologi(Swepub:umu)ansj0004 (author)
  • Gelhaus, H. Carl (author)
  • Fleming, Perry (author)
  • McRae, Kevan (author)
  • Cobb, Ronald R. (author)
  • De Pascalis, Roberto (author)
  • Elkins, Karen L. (author)
  • Umeå universitetMolekylär Infektionsmedicin, Sverige (MIMS) (creator_code:org_t)

Related titles

  • In:Pathogens: MDPI10:72076-0817

Internet link

Find in a library

  • Pathogens (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor
Conlan, J. Wayne
Sjöstedt, Anders
Gelhaus, H. Carl
Fleming, Perry
McRae, Kevan
Cobb, Ronald R.
show more...
De Pascalis, Rob ...
Elkins, Karen L.
show less...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Basic Medicine
and Microbiology in ...
Articles in the publication
Pathogens
By the university
Umeå University

Search outside SwePub

Wikipedia about the author:
J_Wayne_Conlan
Conlan, J. Wayne
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view